Enzo Biochem (ENZ)
(Delayed Data from NYSE)
$1.11 USD
-0.02 (-1.77%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $1.12 +0.01 (0.90%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Enzo Biochem, Inc falls in the month of July .
All items in Millions except EPS data.
7/31/24 | 7/31/23 | 7/31/22 | 7/31/21 | 7/31/20 | |
---|---|---|---|---|---|
Sales | NA | 31 | 107 | 118 | 76 |
Cost Of Goods | NA | 20 | 65 | 64 | 52 |
Gross Profit | NA | 12 | 42 | 54 | 24 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 36 | 57 | 53 | 54 |
Income After Depreciation & Amortization | 0 | -25 | -15 | 1 | -30 |
Non-Operating Income | NA | 0 | -3 | 7 | 2 |
Interest Expense | NA | 0 | 0 | 0 | 0 |
Pretax Income | NA | -25 | -18 | 8 | -29 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -25 | -18 | 8 | -29 |
Extras & Discontinued Operations | NA | 45 | 0 | 0 | 0 |
Net Income (GAAP) | NA | 20 | -18 | 8 | -29 |
Depreciation Footnote | 7/31/24 | 7/31/23 | 7/31/22 | 7/31/21 | 7/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -22 | -12 | 3 | -28 |
Depreciation & Amortization (Cash Flow) | NA | 3 | 3 | 3 | 3 |
Income After Depreciation & Amortization | 0 | -25 | -15 | 1 | -30 |
Earnings Per Share Data | 7/31/24 | 7/31/23 | 7/31/22 | 7/31/21 | 7/31/20 |
---|---|---|---|---|---|
Average Shares | NA | 49.16 | 48.59 | 48.33 | 47.70 |
Diluted EPS Before Non-Recurring Items | NA | -0.51 | -0.23 | 0.21 | -0.51 |
Diluted Net EPS (GAAP) | NA | 0.41 | -0.38 | 0.16 | -0.60 |
Fiscal Year end for Enzo Biochem, Inc falls in the month of July .
All items in Millions except EPS data.
7/31/24 | 4/30/24 | 1/31/24 | 10/31/23 | 7/31/23 | |
---|---|---|---|---|---|
Sales | NA | 8.02 | 8.55 | 7.81 | -19.66 |
Cost Of Goods | NA | 4.29 | 4.33 | 4.35 | -24.72 |
Gross Profit | NA | 3.73 | 4.22 | 3.46 | 5.06 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 5.78 | 6.41 | 8.93 | -8.74 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -2.05 | -2.19 | -5.47 | 13.80 |
Non-Operating Income | NA | -0.09 | 1.32 | -0.20 | -1.68 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -2.13 | -0.86 | -5.68 | 12.12 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -2.13 | -0.86 | -5.68 | 12.12 |
Extras & Discontinued Operations | NA | -0.89 | -2.20 | -0.94 | 45.31 |
Net Income (GAAP) | NA | -3.02 | -3.06 | -6.62 | 57.43 |
Earnings Per Share Data | 7/31/24 | 4/30/24 | 1/31/24 | 10/31/23 | 7/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 51.21 | 50.49 | 50.18 | NA |
Diluted EPS Before Non-Recurring Items | NA | -0.03 | 0.00 | -0.11 | NA |
Diluted Net EPS (GAAP) | NA | -0.06 | -0.06 | -0.13 | 1.17 |